Guardant Shield™ Multi-Cancer Detection

The multi-cancer detection (MCD) test offered by Guardant Health, is a bloodbased test which is intended to detect 10 cancers: Bladder, Breast, Colorectal, Esophageal, Gastric (Stomach), Liver (Hepatocellular), Lung, Pancreatic, Prostate and Ovarian.

Cancer screening can help detect cancer before any symptoms appear. By the time symptoms develop, cancer is often already at a more advanced stage.¹ Early detection improves the chances of survival and can reduce the risk of death.¹⁻³ MCD test* may help more people get screened by using a single blood test to look for signals of different cancers.²

The Guardant Health’s MCD test* is not indicated for use in pregnant women and for people with a known diagnosis of cancer Your clinical eligibility for Guardant Health’s MCD test* will be determined by the medical provider with whom you have scheduled your appointment. There are no other restrictions to taking the test.

Performance & Accuracy⁴

- Sensitivity 60%

- Specificty 99%

Shield MCD covers 10 cancer types:

• Bladder
• Breast
• Colorectal
• Esophageal
• Gastric
• Liver
• Lung
• Ovarian
• Pancreatic
• Prostate

Intended For:

• No pregnancy
• No known cancer history

Standard blood draw — specific tube per Guardant Shield kit

40 mL peripheral blood collected into 4 × Streck Cell-Free DNA BCT® tubes. Collected by a licensed healthcare professional.

Guardant Shield™ is available through Codex Genetics as the authorised Guardant Health distributor in Hong Kong.

1. You can place an order on our E-Shop here.

2. After the order is confirmed, we will contact you by phone within two business days to help arrange an appointment. You may also call +852 3008 2562 or make an appointment via WhatsApp/WeChat at +852 9504 7481.

3. During the call/WhatsApp, we will:

   • Collect basic personal information (e.g. name and date of birth)
   • Provide the address of the designated clinic
   • Offer available appointment time slots for your selection

4. To ensure sample quality and transportation arrangements to the United States, medical consultation and blood collection can only be scheduled Monday to Friday. Appointments are not available on Saturdays, Sundays, or public holidays.

5. Once the appointment is confirmed, you will receive a confirmation message and important notes via WhatsApp or WeChat. We will also reconfirm that your personal information is correct.

6. On the day of your blood draw:

   • Bring your original identification document to the clinic for registration
   • Staff will arrange your medical consultation and blood collection (approximately 30–45 minutes)
   • No fasting or special preparation is required
   • The date for explaining your test report will be scheduled on the same day

7. After the blood draw, our staff will collect and transport your sample to the laboratory. You do not need to, and should not, take the sample out of the clinic yourself.

8. The test report will be completed approximately 2–3 weeks after the sample arrives at the Guardant Health laboratory in the United States. It will then be sent to the clinic where you had your consultation.

9. You may visit the clinic at your scheduled date and time, where the doctor will explain the report to you.

Results are qualitative (positive or negative). For queries on results interpretation, please direct them to the doctor who has been assigned to you for your MCD test. Your clinic will also provide a Fact Sheet together with your test results which can help you to understand the MCD test better.

Clinical Evidence & Guidelines

Received US FDA breakthrough device designation^.

*Your clinical eligibility will be determined by the medical provider with whom you have scheduled your appointment. ^The US FDA Breakthrough Device designation referenced includes eight cancer types—bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic cancer.

Reference:

1. Madar, S.; Amor, R.E.; Furman-Assaf, S.; Friedman, E. Innovative Approaches to Early 51867. https://doi.org/10.3390/cancers17111867
2. Carbonell C, Hutchinson JM, Hilsden RJ, Yang H, Brenner DR. Blood-Based MultiCancer Early Detection Tests (MCEDs) as a Potential Approach to Address Current Gaps in Cancer Screening. Cancer Control. 2024 JanDec;31:10732748241307360. doi: 10.1177/10732748241307360
3. Montena, J. (2024). Early cancer diagnosis: A crucial step toward better outcomes. Journal of Cancer Diagnosis, 2024(1), 1–5
4. He Y, Forouzmand E, Burke J, et al. Validation of a plasma cell-free DNA methylation-based multi-cancer detection test. Abstract 10550. Presented at: 2025 ASCO Annual Meeting; May 30-June 3, 2025; Chicago, IL.